Skip to Content
Find More Like This
Return to Search

Drug screens based on the newly found role of dystroglycan proteolysis and restoration of dystroglycan function thereof

United States Patent

February 23, 2010
View the Complete Patent at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
The present invention provides methods and compositions for the diagnosis and treatment of cells lacking normal growth arresting characteristic. The present invention demonstrates that many tumor cells lack normal cell surface .alpha.-dystroglycan and thereby lack dystroglycan function. Dystroglycan can be lost from the cell surface by proteolytic shedding of a fragment of .alpha.-dystroglycan into the surrounding medium. Upon restoration of dystroglycan function and over-expression of the dystroglycan gene, the once tumorigenic cells revert to non-tumorigenic cells which polarize and arrest cell growth in the presence of basement membrane proteins, demonstrating that dystroglycan functions as a tumor marker and suppressor.
Bissell; Mina J. (Berkeley, CA), Muschler; John L. (Albany, CA)
The Regents of the University of California (Oakland, CA)
11/ 150,406
June 9, 2005
STATEMENT OF GOVERNMENTAL SUPPORT This invention was made during work supported by U.S. Department of Energy under Contract No. DE-AC02-05CH11231 between the U.S. Department of Energy and the University of California for the operation of Lawrence Berkeley National Laboratory (LBNL). The U.S. Government has certain rights in this invention.